I may be mistaken, but I don't think the other indications are...

I may be mistaken, but I don't think the other indications are meant in terms of the application targeting indications beyond Generalized Anxiety Disorder. I think Mark mentioned them because as part of the IND, the company is collating data for psilocybin across other clinical trials for other indications as part of presenting a full profile of the main active ingredient of their drug candidate. I'd be pleased to be wrong, naturally.

I would really like to know what the trial design and stages are going to look like with Psi-GAD. Are we going straight for pivotal trials next year with a phase 2/phase 3 blended design like IHL-42x? If anyone knows this, please share!